Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
26
NVO Quote, Financials, Valuation and Earnings
Last price:
$87.31
Seasonality move
:
6.58%
Day range:
$85.99 - $89.10
52-week range:
$81.50 - $148.15
Dividend yield:
1.63%
P/E ratio:
28.75x
P/S ratio:
10.07x
P/B ratio:
21.83x
Volume:
18.8M
Avg. volume:
7.4M
1-year change:
-13.63%
Market cap:
$394B
Revenue:
$33.7B
EPS (TTM):
$3.09
Analysts' Opinion
-
Consensus RatingNovo Nordisk AS has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $122.11, Novo Nordisk AS has an estimated upside of 37.76% from its current price of $88.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $79.89 representing 100% downside risk from its current price of $88.71.
Fair Value
-
According to the consensus of 8 analysts, Novo Nordisk AS has 37.76% upside to fair value with a price target of $122.11 per share.
NVO vs. S&P 500
-
Over the past 5 trading days, Novo Nordisk AS has underperformed the S&P 500 by -19.3% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Novo Nordisk AS does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novo Nordisk AS has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Novo Nordisk AS reported revenues of $10.5B.
Earnings Growth
-
Novo Nordisk AS has grown year-over-year earnings for 9 quarters straight. In the most recent quarter Novo Nordisk AS reported earnings per share of $0.90.
Enterprise value:
391.3B
EV / Invested capital:
14.72x
Price / LTM sales:
10.07x
EV / EBIT:
22.10x
EV / Revenue:
9.94x
PEG ratio (5yr expected):
1.02x
EV / Free cash flow:
39.81x
Price / Operating cash flow:
40.32x
Enterprise value / EBITDA:
19.42x
Gross Profit (TTM):
$33.3B
Return On Assets:
28.14%
Net Income Margin (TTM):
35.03%
Return On Equity:
88.95%
Return On Invested Capital:
65.63%
Operating Margin:
47.43%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $24.3B | $30.8B | $39.4B | $8.6B | $10.5B | |
| Gross Profit | $20.5B | $25.9B | $33.3B | $7.2B | $8.8B | |
| Operating Income | $10.4B | $13.4B | $17.2B | $3.9B | $5B | |
| EBITDA | $11.6B | $14.1B | $20.2B | $4.8B | $5.5B | |
| Diluted EPS | $1.68 | $2.41 | $3.09 | $0.73 | $0.90 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $11.6B | $14.2B | $15.8B | $20.1B | $29.2B | |
| Total Assets | $22.1B | $27.2B | $32.1B | $42.5B | $59.5B | |
| Current Liabilities | $11.2B | $13.8B | $17.2B | $24.4B | $31.2B | |
| Total Liabilities | $12.7B | $16.8B | $22B | $29.3B | $41.5B | |
| Total Equity | $9.4B | $10.3B | $10.1B | $13.2B | $18.1B | |
| Total Debt | $647.1M | $2.1B | $3.4B | $3.8B | $8.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.3B | $16B | $17.3B | $6B | $6.7B | |
| Cash From Investing | -$4.8B | -$6.3B | -$7.7B | -$1.9B | -$3.1B | |
| Cash From Financing | -$5.3B | -$9.1B | -$5.6B | -$2.9B | -$2.7B | |
| Free Cash Flow | $7.7B | $11.8B | $9.8B | $4.4B | $4.7B | |
NVO
Sector
Market Cap
$394B
$45.6M
Price % of 52-Week High
59.88%
45.55%
Dividend Yield
1.63%
0%
Shareholder Yield
1.65%
-0.74%
1-Year Price Total Return
-13.63%
-31.35%
Beta (5-Year)
0.400
0.772
Dividend yield:
1.63%
Annualized payout:
$1.03
Payout ratio:
46.98%
Growth streak:
4 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$101.84
200-day SMA
Sell
Level
$126.03
Bollinger Bands (100)
Sell
Level
106.53 - 131.27
Chaikin Money Flow
Buy
Level
408.8M
20-day SMA
Sell
Level
$105.84
Relative Strength Index (RSI14)
Sell
Level
27.28
ADX Line
Sell
Level
18.45
Williams %R
Neutral
Level
-76.7569
50-day SMA
Sell
Level
$108.65
MACD (12, 26)
Sell
Level
-3.53
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
56.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.118)
Buy
CA Score
(Annual)
Level (0.8259)
Buy
Beneish M-Score
(Annual)
Level (-2.5531)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-1.5637)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Stock Forecast FAQ
In the current month, NVO has received 5 Buy ratings 2 Hold ratings, and 1 Sell ratings. The NVO average analyst price target in the past 3 months is $122.11.
-
Where Will Novo Nordisk AS Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novo Nordisk AS share price will rise to $122.11 per share over the next 12 months.
-
What Do Analysts Say About Novo Nordisk AS?
Analysts are divided on their view about Novo Nordisk AS share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novo Nordisk AS is a Sell and believe this share price will drop from its current level to $79.89.
-
What Is Novo Nordisk AS's Price Target?
The price target for Novo Nordisk AS over the next 1-year time period is forecast to be $122.11 according to 8 Wall Street analysts, 5 of them rate the stock a Buy, 1 rates the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is NVO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novo Nordisk AS is a Buy. 5 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NVO?
You can purchase shares of Novo Nordisk AS via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novo Nordisk AS shares.
-
What Is The Novo Nordisk AS Share Price Today?
Novo Nordisk AS was last trading at $87.31 per share. This represents the most recent stock quote for Novo Nordisk AS. Yesterday, Novo Nordisk AS closed at $88.71 per share.
-
How To Buy Novo Nordisk AS Stock Online?
In order to purchase Novo Nordisk AS stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 19.35% over the past day.
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 7.91% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 1.39% over the past day.
